The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.
Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial*
Open accessAbstract
OBJECTIVE: To determine the efficacy of anakinra (recombinant interleukin-1 receptor antagonist) in improving 28-day survival in sepsis patients with features of macrophage activation syndrome. Despite equivocal results in sepsis trials, anakinra is effective in treating macrophage activation syndrome, a similar entity with fever, disseminated intravascular coagulation, hepatobiliary dysfunction, cytopenias, and hyperferritinemia. Hence, sepsis patients with macrophage activation syndrome features may benefit from interleukin-1 receptor blockade. DESIGN: Reanalysis of deidentified data from the phase III randomized interleukin-1 receptor antagonist trial in severe sepsis. SETTING: Multicenter study recruiting through 91 centers from 11 countries in Europe and North America. PATIENTS: Sepsis patients with multiorgan dysfunction syndrome and/or shock (original study) were regrouped based on the presence or the absence of concurrent hepatobiliary dysfunction and disseminated intravascular coagulation as features of macrophage activation syndrome. The non-hepatobiliary dysfunction/disseminated intravascular coagulation group included patients with only hepatobiliary dysfunction, only disseminated intravascular coagulation, or neither. INTERVENTION: Treatment with anakinra or placebo. MEASUREMENTS AND MAIN RESULTS: Main outcome was 28-day mortality. Descriptive and comparative statistics were performed. Data were available for 763 adults from the original study cohort, randomized to receive either anakinra or placebo. Concurrent hepatobiliary dysfunction/disseminated intravascular coagulation was noted in 43 patients (5.6% of total; 18-75 years old; 47% women). The 28-day survival was similar in both anakinra and placebo-treated non-hepatobiliary dysfunction/disseminated intravascular coagulation patients (71.4% vs 70.8%; p = 0.88). Treatment with anakinra was associated with significant improvement in the 28-day survival rate in hepatobiliary dysfunction/disseminated intravascular coagulation patients (65.4% anakinra vs 35.3% placebo), with hazard ratio for death 0.28 (0.11-0.71; p = 0.0071) for the treatment group in Cox regression. CONCLUSIONS: In this subgroup analysis, interleukin-1 receptor blockade was associated with significant improvement in survival of patients with sepsis and concurrent hepatobiliary dysfunction/disseminated intravascular coagulation. A prospective randomized trial using features of macrophage activation syndrome for mortality risk stratification should be undertaken to confirm the role of interleukin-1 blockage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, reanalysis of a negative trial of interleukin-1β blockade in patients with sepsis identified a subgroup of patients with elevated ferritin levels who seemed to benefit from the treatment.63”
From Cytokine storm (2020) · cites this paper as [63]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference
Levy, M. M., Fink, M. P., Marshall, J. C., Abraham, E. H., Angus, D. C., Cook, D., Cohen, J., Opal, S. M., Vincent, J., & Ramsay, G. (2003) · Critical Care Medicine · doi:10.1097/01.ccm.0000050454.01978.3b · Cited by 5,976
Self-citationThe Pathophysiology and Treatment of Sepsis
Hotchkiss, R. S., & Karl, I. E. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021333 · Cited by 4,132
An Expanded Definition of the Adult Respiratory Distress Syndrome
Murray, J. F., Matthay, M. A., Luce, J. M., & Flick, M. R. (1988) · American Review of Respiratory Disease · doi:10.1164/ajrccm/138.3.720 · Cited by 2,641
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
Dinarello, C. A. (2011) · Blood · doi:10.1182/blood-2010-07-273417 · Cited by 2,248
Self-citationTreating inflammation by blocking interleukin-1 in a broad spectrum of diseases
Dinarello, C. A., Simon, A., & van der Meer, J. W. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3800 · Cited by 1,810
Self-citationFardet, L., Galicier, L., Lambotte, O., Marzac, C., Aumont, C., Chahwan, D., Coppo, P., & Hejblum, G. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38690 · Cited by 1,508
Interleukin-1 and the Pathogenesis of the Acute-Phase Response
Epstein, F. H., & Dinarello, C. A. (1984) · New England Journal of Medicine · doi:10.1056/nejm198411293112205 · Cited by 1,151
Self-citationConfirmatory interleukin-1 receptor antagonist trial in severe sepsis
Opal, S. M., Fisher, C. J., Dhainaut, J.-F., Vincent, J., Brase, R., Lowry, S. F., SADOFF, J. C., Slotman, G. J., Levy, H. A., BALK, R. A., et al. (1997) · Critical Care Medicine · doi:10.1097/00003246-199707000-00010 · Cited by 882
Self-citationHighly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis
Allen, C. E., Yu, X., Kozinetz, C. A., & McClain, K. L. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21423 · Cited by 637
Research works printed but not linked: 4
- Emmenegger, 2005, Swiss Med Wkly, 135, 299
- Behrens, 2007, J Rheumatol, 34, 1133
- Behrens, 2006, J Rheumatol, 33, 2081
- Marti-Carvajal, 2012, Cochrane Database Syst Rev, 12, CD004388
Cited by
Sorted by citations
Items 201–300 of 871
Franzetti, M., Molinari, A. F., Borsa, N., Pandolfo, A., Molteni, C., Borghesi, L., Pontiggia, S., Evasi, G., Guiotto, L., Erba, M., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2001126 · Cited by 67
Pediatric macrophage activation syndrome, recognizing the tip of the Iceberg
Crayne, C. B., & Cron, R. Q. (2019) · European Journal of Rheumatology · doi:10.5152/eurjrheum.2019.19150 · Cited by 67
Self-citationPain, C. E., Felsenstein, S., Cleary, G., Mayell, S. J., Conrad, K., Harave, S., Duong, P., Sinha, I. P., Porter, D., & Hedrich, C. M. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30137-5 · Cited by 66
Lin, H., Scull, B., Goldberg, B. R., Abhyankar, H. A., Eckstein, O. S., Zinn, D. J., Lubega, J., Agrusa, J. E., Mallawaney, N. E., Gulati, N., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004287 · Cited by 69
Inner sensors of endotoxin – implications for sepsis research and therapy
Skirecki, T., & Cavaillon, J. (2019) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuz004 · Cited by 64
Kellum, J. A., Formeck, C. L., Kernan, K. F., Gómez, H., & Carcillo, J. A. (2022) · Critical Care Clinics · doi:10.1016/j.ccc.2021.11.013 · Cited by 62
Self-citationKotsaki, A., Pickkers, P., Bauer, M. W., Calandra, T., Lupșe, M. S., Wiersinga, W. J., Meylan, S., Bloos, F., van der Poll, T., Slim, M. A., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-067251 · Cited by 63
Iglesias-Julián, E., López-Veloso, M., de-la-Torre-Ferrera, N., Barraza-Vengoechea, J. C., Delgado-López, P. D., Colazo-Burlato, M., Ubeira-Iglesias, M., Montero-Baladía, M., Lorenzo-Martín, A., Minguito-de-la-Iglesia, J., et al. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102537 · Cited by 62
Intravenous administration of anakinra in children with macrophage activation syndrome
Phadke, O., Rouster‐Stevens, K. A., Giannopoulos, H. T., Chandrakasan, S., & Prahalad, S. (2021) · Pediatric Rheumatology · doi:10.1186/s12969-021-00585-3 · Cited by 63
The coming era of precision medicine for intensive care
Vincent, J. (2017) · Critical Care · doi:10.1186/s13054-017-1910-z · Cited by 63
Shakoory, B., Geerlinks, A. V., Wilejto, M., Kernan, K. F., Hines, M., Romano, M., Piskin, D., Ravelli, A., Sinha, R. R., Aletaha, D., et al. (2023) · Arthritis & Rheumatology · doi:10.1002/art.42636 · Cited by 60
Self-citationSepsis in patients who are immunocompromised: diagnostic challenges and future therapies
Deinhardt‐Emmer, S., Chousterman, B. G., Schefold, J. C., Flohé, S. B., Skirecki, T., Kox, M., Winkler, M. S., Cossarizza, A., Wiersinga, W. J., van der Poll, T., et al. (2025) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(25)00124-9 · Cited by 60
Knaak, C., Schuster, F. S., Nyvlt, P., Spies, C., Feinkohl, I., Beutel, G., Schenk, T., Rosée, P. G. L., Janka, G., Brunkhorst, F. M., et al. (2020) · Critical Care Medicine · doi:10.1097/ccm.0000000000004581 · Cited by 59
SARS‐CoV‐2‐mediated immune system activation and potential application in immunotherapy
Tan, Y., & Tang, F. (2020) · Medicinal Research Reviews · doi:10.1002/med.21756 · Cited by 59
Qin, Y., Kernan, K. F., Fan, Z., Park, H. J., Kim, S., Canna, S., Kellum, J. A., Berg, R. A., WESSEL, D. L., Pollack, M. M., et al. (2022) · Critical Care · doi:10.1186/s13054-022-03977-3 · Cited by 59
Self-citationThe immunology of sepsis: translating new insights into clinical practice
Kox, M., Bauer, M. W., Bos, L. D. J., Bouma, H. R., Calandra, T., Calfee, C. S., Chousterman, B. G., Derde, L. P. G., Giamarellos‐Bourboulis, E. J., Gómez, H., et al. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-025-01004-6 · Cited by 76
Walborn, A., Rondina, M. T., Mosier, M. M., Fareed, J., & Hoppensteadt, D. (2019) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029619852163 · Cited by 59
Liver injury in sepsis: manifestations, mechanisms and emerging therapeutic strategies
Xu, X., Yang, T., An, J., Li, B., & Dou, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1575554 · Cited by 68
How Clinical Flow Cytometry Rebooted Sepsis Immunology
Monneret, G., Gossez, M., Aghaeepour, N., Gaudilliere, B. L., & Venet, F. (2019) · Cytometry Part A · doi:10.1002/cyto.a.23749 · Cited by 59
Advances in the possible treatment of COVID-19: A review.
Chibber, P., Haq, S. A., Ahmed, I., Andrabi, N. I., & Singh, G. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173372 · Cited by 56
Pro-inflammatory properties of H-ferritin on human macrophages, ex vivo and in vitro observations
Ruscitti, P., Benedetto, P. D., Berardicurti, O., Panzera, N., Grazia, N., Lizzi, A. R., Cipriani, P., Shoenfeld, Y., & Giacomelli, R. (2020) · Scientific Reports · doi:10.1038/s41598-020-69031-w · Cited by 59
Dulek, D. E., Fuhlbrigge, R. C., Tribble, A. C., Connelly, J. A., Loi, M. M., Chebib, H. E., Chandrakasan, S., Otto, W. R., Diorio, C. J., Keim, G. P., et al. (2020) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piaa098 · Cited by 56
Self-citationGasdermin D (GSDMD) as a new target for the treatment of infection
Pandeya, A., Li, L., Li, Z., & Wei, Y. (2019) · MedChemComm · doi:10.1039/c9md00059c · Cited by 55
CORONAVIRUS DISEASE 2019 (COVID-19): A RHEUMATOLOGIST’S THOUGHTS
Nasonov, E. L. (2020) · Rheumatology Science and Practice · doi:10.14412/1995-4484-2020-123-132 · Cited by 59
Střı́ž, I. (2017) · Clinical Science · doi:10.1042/cs20170098 · Cited by 54
Parisi, F., Paglionico, A., Varriano, V., Ferraccioli, G., & Gremese, E. (2017) · Medicine · doi:10.1097/md.0000000000006656 · Cited by 54
Haemophagocytic lymphohistiocytosis in adult critical care
Bauchmüller, K., Manson, J. J., Tattersall, R. S., Brown, M., McNamara, C., Singer, M., & Brett, S. J. (2020) · Journal of the Intensive Care Society · doi:10.1177/1751143719893865 · Cited by 54
Fernández, J., Gratacós‐Ginès, J., Olivas, P., Costa, M., Nieto, S., Mateo, D., Sánchez, M. B., Aguilar, F., Bassegoda, O., Ruíz, P., et al. (2020) · Critical Care Medicine · doi:10.1097/ccm.0000000000004613 · Cited by 53
Sheng, C. C., Sahoo, D. H., Dugar, S. P., Prada, R. A., Wang, T. K. M., Hassan, O. K. A., Brennan, D. M., Culver, D. A., Rajendram, P., Duggal, A., et al. (2020) · Clinical Cardiology · doi:10.1002/clc.23451 · Cited by 51
Barkas, F., Filippas-Ntekouan, S., Kosmidou, M. S., Liberopoulos, E. N., Liontos, A., & Milionis, H. J. (2021) · Rheumatology · doi:10.1093/rheumatology/keab447 · Cited by 50
The role of NLRP3 inflammasome in sepsis: A potential therapeutic target
He, W., Dong, H., Wu, C., Zhong, Y., & Li, J. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109697 · Cited by 56
The Potential of Phage Therapy in Sepsis
Górski, A., Jończyk‐Matysiak, E., Łusiak-Szelachowska, M., Międzybrodzki, R., Weber‐Dąbrowska, B., & Borysowski, J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01783 · Cited by 50
Song, F., Hou, J., Chen, Z., Cheng, B., Lei, R., Cui, P., Sun, Y., Wang, H., & Fang, X. (2018) · Anesthesiology · doi:10.1097/aln.0000000000002196 · Cited by 50
Sandler, R. D., Carter, S. J., Kaur, H., Francis, S., Tattersall, R. S., & Snowden, J. A. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0637-7 · Cited by 50
Yokota, S., Miyamae, T., Kuroiwa, Y., & Nishioka, K. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040801 · Cited by 47
Hong, Y., Chen, L., Sun, J., Xing, L., Yang, Y. L., Jin, X., Cai, H., Dong, L., Zhou, L., & Zhang, Z. (2022) · iScience · doi:10.1016/j.isci.2022.105301 · Cited by 49
Management of adult-onset Still's disease: evidence- and consensus-based recommendations by experts
Leavis, H. L., van Daele, P. L. A., Mulders‐Manders, C. M., Michels, R. E., Rutgers, A., Legger, G. E., Bijl, M., Hak, E. A., Lam‐Tse, W., Bonte‐Mineur, F., et al. (2023) · Lara D. Veeken · doi:10.1093/rheumatology/kead461 · Cited by 49
Personalized Therapy Approach for Hospitalized Patients with Coronavirus Disease 2019
Garcia-Vidal, C., Moreno-García, E., Hernández-Meneses, M., Puerta-Alcalde, P., Chumbita, M., Garcia-Pouton, N., Linares, L., Rico, V., Cardozo, C., Martínez, J. A., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa964 · Cited by 48
Muskardin, T. W. (2020) · ACR Open Rheumatology · doi:10.1002/acr2.11140 · Cited by 48
Current evidence on the use of anakinra in COVID-19
Khani, E., Shahrabi, M., Rezaei, H., Pourkarim, F., Afsharirad, H., & Solduzian, M. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109075 · Cited by 51
What are the current anti-COVID-19 drugs? From traditional to smart molecular mechanisms
Aboul‐Fotouh, S., Mahmoud, A. N., Elnahas, E. M., Habib, M. Z., & Abdelraouf, S. M. (2023) · Virology Journal · doi:10.1186/s12985-023-02210-z · Cited by 54
Targeting cytokines to treat autoinflammatory diseases
Hausmann, J. S. (2018) · Clinical Immunology · doi:10.1016/j.clim.2018.10.016 · Cited by 48
The innate immune perspective of autoimmune and autoinflammatory conditions
Frizinsky, S., Yahia, S. H., Machnes‐Maayan, D., Lifshitz, Y., Segal, R. M., Offengenden, I., Kidon, M. I., & Agmon‐Levin, N. (2019) · Rheumatology · doi:10.1093/rheumatology/kez387 · Cited by 50
High Mortality of HLH in ICU Regardless Etiology or Treatment
Bichon, A., Bourenne, J., Allardet-Servent, J., Papazian, L., Hraiech, S., Guervilly, C., Pauly, V., Kaplanski, G., Mokart, D., Gainnier, M., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.735796 · Cited by 48
Towards precision medicine for sepsis patients
Pickkers, P., & Kox, M. (2017) · Critical Care · doi:10.1186/s13054-016-1583-z · Cited by 48
Nandi, M., Jackson, S. K., Macrae, D. J., Shankar‐Hari, M., Tremoleda, J. L., & Lilley, E. J. (2020) · Clinical Science · doi:10.1042/cs20200679 · Cited by 50
Role for Anti-Cytokine Therapies in Severe Coronavirus Disease 2019
Buckley, L. F., Wohlford, G. F., Ting, C., Alahmed, A. A., Tassell, B. W. V., Abbate, A., Devlin, J. W., & Libby, P. (2020) · Critical Care Explorations · doi:10.1097/cce.0000000000000178 · Cited by 48
Bergmann, C. B., Beckmann, N., Salyer, C. E., Crisologo, P. A., Nomellini, V., & Caldwell, C. C. (2020) · Shock · doi:10.1097/shk.0000000000001675 · Cited by 50
Mechanisms and modulation of sepsis-induced immune dysfunction in children
Mithal, L. B., Arshad, M., Swigart, L. R., Khanolkar, A., Ahmed, A. S., & Coates, B. M. (2021) · Pediatric Research · doi:10.1038/s41390-021-01879-8 · Cited by 50
Molecular Mechanisms Underlying Intensive Care Unit-Acquired Weakness and Sarcopenia
Káňová, M., & Kohout, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158396 · Cited by 51
Gander-Bui, H. T. T., Schläfli, J., Baumgartner, J., Walthert, S., Genitsch, V., van Geest, G., Galván, J. A., Cardozo, C., Graham Martinez, C., Grans, M., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.06.023 · Cited by 47
Apoptotic caspase-7 activation inhibits non-canonical pyroptosis by GSDMB cleavage
Li, X., Zhang, T. Y., Kang, L., Xin, R., Sun, M., Chen, Q., Pei, J., Chen, Q., Gao, X., & Lin, Z. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01211-3 · Cited by 48
Hemophagocytic Lymphohistiocytosis in Critically Ill Patients
Knaak, C., Schuster, F. S., Spies, C., Vorderwülbecke, G., Nyvlt, P., Schenk, T., Balzer, F., Rosée, P. G. L., Janka, G., Brunkhorst, F. M., et al. (2019) · Shock · doi:10.1097/shk.0000000000001454 · Cited by 47
Role of immunosuppressive therapy in rheumatic diseases concurrent with COVID-19
Lu, C., Li, S., & Liu, Y. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217460 · Cited by 45
Baldo, F., Erkens, R. G. A., Mizuta, M., Rogani, G., Lucioni, F., Bracaglia, C., Foell, D., Gattorno, M., Jelušić, M., Antón, J., et al. (2024) · Lara D. Veeken · doi:10.1093/rheumatology/keae391 · Cited by 47
Self-citationTuberculosis endotypes to guide stratified host-directed therapy
DiNardo, A. R., Nishiguchi, T., Grimm, S. L., Schlesinger, L. S., Graviss, E. A., Cirillo, J. D., Coarfa, C., Mandalakas, A. M., Heyckendorf, J., Kaufmann, S. H. E., et al. (2021) · Med · doi:10.1016/j.medj.2020.11.003 · Cited by 47
Franzetti, M., Pozzetti, U., Carugati, M., Pandolfo, A., Molteni, C., Faccioli, P., Castaldo, G., Longoni, E., Ormas, V., Iemoli, E., et al. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.05.050 · Cited by 45
Treatment algorithm for COVID-19: a multidisciplinary point of view
Galluccio, F., Ergönenç, T., Martos, Á. G., Allam, A. E.-S., Pérez-Herrero, M. A., Aguilar, R., Emmi, G., Spinicci, M., de Juan, I. T., & Fajardo‐Pérez, M. (2020) · Clinical Rheumatology · doi:10.1007/s10067-020-05179-0 · Cited by 45
Pediatric Inflammatory Multisystem Syndrome and Rheumatic Diseases During SARS-CoV-2 Pandemic
Schvartz, A., Bélot, A., & Koné‐Paut, I. (2020) · Frontiers in Pediatrics · doi:10.3389/fped.2020.605807 · Cited by 47
Kharazmi, A. B., Moradi, O., Haghighi, M., Kouchek, M., Rasi, A. M., Raoufi, M., Shoaei, . D., Hadavand, F., Nabavi, M., Miri, M. M., et al. (2021) · Immunity Inflammation and Disease · doi:10.1002/iid3.563 · Cited by 45
Interleukin-1 blocking agents for treating COVID-19
Davidson, M., Menon, S., Chaimani, A., Evrenoglou, T., Ghosn, L., Graña, C., Henschke, N., Cogo, E., Villanueva, G., Ferrand, G., et al. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015308 · Cited by 48
Anakinra for the Treatment of Hemophagocytic Lymphohistiocytosis: 21 Cases
Baverez, C., Grall, M., Gerfaud‐Valentin, M., Gail, S. D., Bélot, A., Perpoint, T., Weber, E., Reynaud, Q., Sève, P., & Jamilloux, Y. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195799 · Cited by 45
Bindoli, S., Baggio, C., Doria, A., & Sfriso, P. (2024) · Drugs · doi:10.1007/s40265-024-01993-x · Cited by 53
Bindoli, S., Matteis, A. D., Mitrovic, S., Fautrel, B., Carmona, L., & Benedetti, F. D. (2024) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2024-225854 · Cited by 48
Adults with septic shock and extreme hyperferritinemia exhibit pathogenic immune variation
Kernan, K. F., Ghaloul‐Gonzalez, L., Shakoory, B., Kellum, J. A., Angus, D. C., & Carcillo, J. A. (2018) · Genes and Immunity · doi:10.1038/s41435-018-0030-3 · Cited by 45
Self-citationRuscitti, P., Cipriani, P., Benedetto, P. D., Liakouli, V., Carubbi, F., Berardicurti, O., Ciccia, F., Guggino, G., Triolo, G., & Giacomelli, R. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1372194 · Cited by 44
Karakike, E., Scicluna, B. P., Roumpoutsou, M., Mitrou, I., Karampela, N., Karageorgos, A., Psaroulis, K., Massa, E., Pitsoulis, A., Chaloulis, P., et al. (2022) · Critical Care · doi:10.1186/s13054-022-04055-4 · Cited by 42
Green, E. A., Metz, D., Galinsky, R., Atkinson, R., Skuza, E. M., Clark, M., Gunn, A. J., Kirkpatrick, C. M. J., Hunt, R. W., Berger, P. J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1022104 · Cited by 43
Millán, I. F. A., Salvatierra, J., Torres-Parejo, Ú., Faro‐Míguez, N., Callejas-Rubio, J. L., Ceballos-Torres, Á., Cruces-Moreno, M. T., Gómez-Jiménez, F. J., Hernández‐Quero, J., Anguita-Santos, F., et al. (2021) · Internal and Emergency Medicine · doi:10.1007/s11739-020-02600-z · Cited by 44
Agents to reduce cytokine storm
Gerlach, H. (2016) · F1000Research · doi:10.12688/f1000research.9092.1 · Cited by 43
The amount of cytokine-release defines different shades of Sars-Cov2 infection
Bindoli, S., Felicetti, M., Sfriso, P., & Doria, A. (2020) · Experimental Biology and Medicine · doi:10.1177/1535370220928964 · Cited by 44
Overview of COVID-19 Disease: Virology, Epidemiology, Prevention Diagnosis, Treatment, and Vaccines
Salahshoori, I., Mobaraki-Asl, N., Seyfaee, A., Nasirabad, N. M., Dehghan, Z., Faraji, M., Ganjkhani, M., Babapoor, A., Shadmehr, S., & Hamrang, A. (2021) · Biologics · doi:10.3390/biologics1010002 · Cited by 46
Bansal, S., Yajjala, V. K., Bauer, C. D., & Sun, K. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1700210 · Cited by 41
Harnessing Memory NK Cell to Protect Against COVID-19
Soleimanian, S., & Yaghobi, R. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01309 · Cited by 41
Multisystem Inflammatory Syndrome in Children
Waseem, M., Shariff, M. A., Tay, E. T., Mortel, D., Savadkar, S., Lee, H., Kondamudi, N. P., & Liang, T. (2021) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2021.07.070 · Cited by 41
Frohman, E. M., Villemarette-Pittman, N. R., Cruz, R. A., Longmuir, R. A., Rowe, V. D., Rowe, E. S., Varkey, T. C., Steinman, L., Zamvil, S. S., & Frohman, T. C. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.116935 · Cited by 40
Ruscitti, P., Cola, I. D., Muzio, C. D., Italiano, N., Ursini, F., Giacomelli, R., & Cipriani, P. (2022) · Autoimmunity Reviews · doi:10.1016/j.autrev.2022.103114 · Cited by 40
Cancio, M., Ciccocioppo, R., Rocco, P. R. M., Levine, B. L., Bronte, V., Bollard, C. M., Weiss, D. J., Boelens, J. J., & Hanley, P. J. (2020) · Cytotherapy · doi:10.1016/j.jcyt.2020.04.100 · Cited by 41
Colafrancesco, S., Scrivo, R., Barbati, C., Conti, F., & Priori, R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01439 · Cited by 38
Dutta, D., Liu, J., & Xiong, H. (2022) · PubMed Central · Cited by 38
Multi-Omics Endotypes in ICU Sepsis-Induced Immunosuppression
Garduno, A., Cusack, R., Leone, M., Einav, S., & Martin-Loeches, I. (2023) · Microorganisms · doi:10.3390/microorganisms11051119 · Cited by 39
Vella, R., Panci, D., Carini, F., Malta, G., Vieni, S., David, S., Albano, G. D., Puntarello, M., Zerbo, S., & Argo, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1682306 · Cited by 47
Weaver, L. K., & Behrens, E. M. (2017) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-017-0059-x · Cited by 39
Tsoukas, P., Rapp, E., Kraak, L. V. D., Weiss, E. S., Dang, V., Schneider, C., Klein, E. C., Picarsic, J. L., Salcedo, R., Stewart, C. A., et al. (2020) · Blood · doi:10.1182/blood.2019003846 · Cited by 39
Christie, M. J., Irving, A. T., Forster, S. C., Marsland, B. J., Hansbro, P. M., Hertzog, P. J., Nold‐Petry, C. A., & Nold, M. F. (2021) · Science Immunology · doi:10.1126/sciimmunol.abd0205 · Cited by 41
Interleukin-1 and the NLRP3 Inflammasome in Pericardial Disease
Vecchié, A., Buono, M. G. D., Chiabrando, J. G., Dentali, F., Abbate, A., & Bonaventura, A. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01589-x · Cited by 43
Bruserud, Ø., Mosevoll, K. A., Bruserud, Ø., Reikvam, H., & Wendelbo, Ø. (2023) · Cells · doi:10.3390/cells12071003 · Cited by 38
Sztajnbok, F., Fonseca, A. R., Campos, L. R., Lino, K., Rodrigues, M. C. F., Silva, R. M., de Almeida, R. G., Perazzio, S. F., & Carvalho, M. D. F. F. (2024) · Revista Brasileira de Reumatologia · doi:10.1186/s42358-024-00370-2 · Cited by 38
Coronavirus disease 2019 (COVID-19) and autoimmunity
Nasonov, E. L. (2021) · Rheumatology Science and Practice · doi:10.47360/1995-4484-2021-5-30 · Cited by 41
Anderko, R. R., Gómez, H., Canna, S., Shakoory, B., Angus, D. C., Yealy, D. M., Huang, D. T., Kellum, J. A., Carcillo, J. A., For the ProCESS Investigators, et al. (2022) · Intensive Care Medicine Experimental · doi:10.1186/s40635-022-00433-y · Cited by 37
Self-citationUnraveling immunosenescence in sepsis: from cellular mechanisms to therapeutics
Wang, Y., Zhang, H., & Miao, C. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07714-w · Cited by 41
SARS-CoV-2: Pathogenesis, and Advancements in Diagnostics and Treatment
Khalaf, K., Papp, N., Chou, J. T.-T., Hana, D., Mackiewicz, A. A., & Kaczmarek, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.570927 · Cited by 39
Napodano, C., Carnazzo, V., Basile, V., Pocino, K., Stefanile, A., Gallucci, S., Natali, P., Basile, U., & Marino, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316556 · Cited by 38
Zhang, J., Luo, W., Miao, C., & Zhong, J. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.941097 · Cited by 38
Mortality Risk in Pediatric Sepsis Based on C-reactive Protein and Ferritin Levels
Horvat, C. M., Fabio, A., Nagin, D. S., Banks, R., Qin, Y., Park, H. J., Kernan, K. F., Canna, S., Berg, R. A., WESSEL, D. L., et al. (2022) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000003074 · Cited by 36
Self-citationFighting cytokine storm and immunomodulatory deficiency: By using natural products therapy up to now
Mohammed, M. A. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1111329 · Cited by 34
Biochemical indicators of coronavirus disease 2019 exacerbation and the clinical implications
An, P., Zhu, Y. Z., & Yang, L.-P. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104946 · Cited by 35
Bello, B., Bundey, Y., Bhave, R., Khotimchenko, M., Baran, S. W., Chakravarty, K., & Varshney, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076250 · Cited by 34
Ghosh, S., Baranwal, A. K., Bhatia, P., & Nallasamy, K. (2018) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000001584 · Cited by 34
Lorenz, G., Moog, P., Bachmann, Q., Rosée, P. G. L., Schneider, H., Schlegl, M., Spinner, C. D., Heemann, U. W., Schmid, R. M., Algül, H., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-75260-w · Cited by 34
Metadata
- Authors
- Shakoory, B., Carcillo, J. A., Chatham, W. W., Amdur, R. L., Zhao, H., Dinarello, C. A., Cron, R. Q., & Opal, S. M.
- Affiliations
- George Washington University (US)
- University of Pittsburgh Medical Center (US)
- University of Alabama at Birmingham (US)
- Temple University (US)
- University of Colorado Anschutz (US)
- Brown University (US)
- ORCID
- Venue
- Critical Care Medicine
- Published
- 2016-02
- Volume
- 44
- Issue
- 2
- Pages
- 275-281
- ISSN
- 0090-3493 (ISSN-L)
- PMC
- PMC5378312
- OpenAlex
- W2177407033
- Cited by
- 867
- References
- 48
- Citations by year
- 2026: 66 · 2025: 64 · 2024: 68 · 2023: 76 · 2022: 87 · 2021: 141 · 2020: 226 · 2019: 43 · 2018: 36 · 2017: 42 · 2016: 15
- FWCI
- 24.58
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Critical Care Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of General Medical Sciences (R01GM108618)
- Topics
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Life Sciences › Immunology and Microbiology › Immunology › Inflammation biomarkers and pathways
- Keywords
- sepsis, anakinra, interleukin-1 receptor antagonist, interleukin-1 blockade, 28-day mortality, hepatobiliary dysfunction, disseminated intravascular coagulation, multiple organ failure, septic shock, subgroup analysis, hyperferritinemia, cytokine storm
- MeSH terms
- Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Biliary Tract Diseases, Disseminated Intravascular Coagulation, Double-Blind Method, Female, Humans, Liver Diseases, Male, Middle Aged, Multiple Organ Failure, Respiratory Distress Syndrome, Sex Factors, Shock, Septic, Receptors, Interleukin-1, Sepsis, APACHE, Interleukin 1 Receptor Antagonist Protein, Macrophage Activation Syndrome, Young Adult, Acute Kidney Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
